Convertible bonds 2021/2024

Disclaimer

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

You have not entered a valid address outside the United States of America, Canada, Japan and Australia. We therefore regret that we cannot provide you with the desired information. Should you be a shareholder of Epigenomics AG please contact Investor Relations regarding further information on the rights offering at:

Epigenomics AG
Investor Relations
Tel: +49 30-24245-386
E-Mail: ir@epigenomics.com